Daria Mochly-Rosen
Director/Board Member at California Biomedical Innovation Alliance
Profile
Daria Mochly-Rosen is the founder of Aldea Pharmaceuticals, Inc. (founded in 2011), Mitoconix Bio Ltd.
(founded in 2016), and KAI Pharmaceuticals, Inc. (founded in 2002).
She is currently a Director at California Biomedical Innovation Alliance (since 2017) and a Professor at Stanford University School of Medicine (current job).
Her former jobs include Chairman at Molecular Pharmacology (USA) Ltd.
(2002-2006), Principal at Translational Medicine India, Inc., and Faculty Member at Stanford University.
Dr. Mochly-Rosen received her undergraduate degree from Tel-Aviv University and her doctorate from Weizmann Institute of Science.
Daria Mochly-Rosen active positions
| Companies | Position | Start |
|---|---|---|
California Biomedical Innovation Alliance
 California Biomedical Innovation Alliance BiotechnologyHealth Technology California Biomedical Innovation Alliance provides biomedical advocacy and community services. The private company is based in South San Francisco, CA and has subsidiaries in United States. The CEO of the company is Sara Radcliffe. | Director/Board Member | 13/02/2017 |
| Stanford University School of Medicine | Corporate Officer/Principal | - |
Former positions of Daria Mochly-Rosen
| Companies | Position | End |
|---|---|---|
| MOLECULAR PHARMACOLOGY (USA), LTD. | Chairman | 01/01/2006 |
Mitoconix Bio Ltd.
 Mitoconix Bio Ltd. BiotechnologyHealth Technology Mitoconix Bio Ltd. develops novel therapeutics to improve mitochondrial health as a disease-modifying therapeutics for neurodegenerative diseases. The company was founded by Daria Mochly-Rosen in August 2016 and is headquartered in Ness Ziona, Israel. | Founder | - |
Aldea Pharmaceuticals, Inc.
 Aldea Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aldea Pharmaceuticals, Inc. develops novel enzyme activators to enhance the removal of toxic aldehydes. It targets Aldehyde metabolism dysfunction which is associated with a variety of diseases from acute alcohol toxicity to orphan indications such as Fanconi anemia. The company was founded by Daria Mochly-Rosen, Che-Hong Chen and Wenjin Yang in 2011 and is headquartered in Redwood City, CA. | Founder | - |
Translational Medicine India, Inc.
 Translational Medicine India, Inc. Miscellaneous Commercial ServicesCommercial Services Translational Medicine India, Inc. provides clinical research solutions. It offers a novel therapeutic with biomarkers and early stage clinical trials for researchers. The company is headquartered in Waltham, MA. | Corporate Officer/Principal | - |
| Stanford University | Corporate Officer/Principal | - |
Training of Daria Mochly-Rosen
| Tel-Aviv University | Undergraduate Degree |
| Weizmann Institute of Science | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| MOLECULAR PHARMACOLOGY (USA), LTD. | Commercial Services |
| Private companies | 5 |
|---|---|
KAI Pharmaceuticals, Inc.
 KAI Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology KAI Pharmaceuticals, Inc. discovers and develops biopharmaceutical drugs. It is a multiple, novel clinical-stage programs in the areas of cardiovascular, renal, and pain. The company was founded in 2002 and is headquartered in South San Francisco, CA. | Health Technology |
Translational Medicine India, Inc.
Translational Medicine India, Inc. Miscellaneous Commercial ServicesCommercial Services Translational Medicine India, Inc. provides clinical research solutions. It offers a novel therapeutic with biomarkers and early stage clinical trials for researchers. The company is headquartered in Waltham, MA. | Commercial Services |
Aldea Pharmaceuticals, Inc.
Aldea Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aldea Pharmaceuticals, Inc. develops novel enzyme activators to enhance the removal of toxic aldehydes. It targets Aldehyde metabolism dysfunction which is associated with a variety of diseases from acute alcohol toxicity to orphan indications such as Fanconi anemia. The company was founded by Daria Mochly-Rosen, Che-Hong Chen and Wenjin Yang in 2011 and is headquartered in Redwood City, CA. | Health Technology |
California Biomedical Innovation Alliance
California Biomedical Innovation Alliance BiotechnologyHealth Technology California Biomedical Innovation Alliance provides biomedical advocacy and community services. The private company is based in South San Francisco, CA and has subsidiaries in United States. The CEO of the company is Sara Radcliffe. | Health Technology |
Mitoconix Bio Ltd.
Mitoconix Bio Ltd. BiotechnologyHealth Technology Mitoconix Bio Ltd. develops novel therapeutics to improve mitochondrial health as a disease-modifying therapeutics for neurodegenerative diseases. The company was founded by Daria Mochly-Rosen in August 2016 and is headquartered in Ness Ziona, Israel. | Health Technology |
- Stock Market
- Insiders
- Daria Mochly-Rosen
